Boehringer Ingelheim extends collaboration with Evotec
3 November 2005 00:00 in Company product news
German pharmaceutical giant Boehringer Ingelheim has extended the scope of its collaboration with Evotec.
Evotec, which operates in Germany and the UK, will collaborate with Boehringer under a fee-for-service agreement focused on selected Boehringer target proteins.
Evotec will utilise biochemical and cellular assay development as well as ultra-high-throughput screening (uHTS) using its proprietary FCS+plus detection platform.
Active compounds discovered will be further progressed by Boehringer to develop novel treatments for different diseases.
Professor Mikael Dolsten, head of pharma research and discovery at Boehringer Ingelheim, said: "Evotec has a strong track record in performing uHTS screens and handling large compound pools in complex assays. Evotec's proprietary detection technology also offers sensitive and robust systems for hit identification."
The two companies already have a joint discovery programme to identify and develop therapeutics acting on G-Protein Coupled Receptors (GPCRs).
Boehringer was boosted in October when the European Commission cleared the company to market its HIV drug Aptivus (tipravanir) for treatment of HIV in combination with other anti-retroviral agents. © Adfero Ltd
Other news stories from 03/11/2005
Read more in the Zenopa News Archive
How this news is generated
Story collated for Zenopa by the Adfero News Agency